Long‐term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease

Lirussi, Flavio; Beccarello, Alessandro; Bortolato, L.; Morselli-Labate, Antonio Maria; Crovatto, M; Ceselli, S; Santini, Gianfranco; Crepaldi, Gaetano

doi:10.1111/j.1478-3231.1999.tb00066.x

Cited by 27 publications

(16 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results suggested that 900 mg of UDCA can improve liver function tests in patients with chronic hepatitis C who have already received 600 mg of UDCA. In this study, the frequency of adverse events was lower than those in previous reports [15][16][17][18] . A possible reason for this is that patients enrolled in this study were not naïve to UDCA and may have quickly gotten used to the administration of UDCA.…”

Section: Discussioncontrasting

confidence: 86%

A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients

Sato

Miyake²,

Tobita³

et al. 2009

WJG

View full text Add to dashboard Cite

AIM:To examine whether a dose-up to 900 mg of ursodeoxycholic acid (UDCA) decreases transaminases in hepatitis C patients. METHODS:From January to December 2007, patients with chronic hepatitis C or compensated liver cirrhosis with hepatitis C virus (HCV) (43-80 years old) showing positive serum HCV-RNA who had already taken 600 mg/d of UDCA were recruited into this study. Blood parameters were examined at 4, 8 and 24 wk after increasing the dose of oral UDCA from 600 to 900 mg/d. RESULTS:Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gammaglutamyl transpeptidase (GGT) levels were significantly decreased following the administration of 900 mg/d as compared to 600 mg/d. The decrease in ALT from immediately before the dose-up of UDCA to 8 wk after the dose-up was 14.3 IU/L, while that for AST was 10.5 IU/L and for GGT was 9.8 IU/L. Platelet count tended to increase after the dose-up of UDCA, although it did not show a statistically significant level (P = 0.05). Minor adverse events were observed in 3 cases, although no drop-outs from the study occurred. CONCLUSION:Oral administration of 900 mg/d of UDCA was more effective than 600 mg/d for reducing ALT, AST, and GGT levels in patients with HCV-related chronic liver disease.

show abstract

Section: Discussioncontrasting

confidence: 86%

A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients

Sato

Miyake²,

Tobita³

et al. 2009

WJG

View full text Add to dashboard Cite

show abstract

“…For the treatment of HCV-infected and relapsed patients, interferon is used separately or in combination with ribavirin or ursodeoxycholic acid [Lirussi et al, 1999;Salmeron et al, 1999]. However, interferon is inconvenient to use and can cause complications.…”

Section: Discussionmentioning

confidence: 99%

Factors predictive of response to interferon‐α therapy in hepatitis C virus type 1b infection

Yeh¹,

Han²,

Lee³

et al. 2002

Journal of Medical Virology

View full text Add to dashboard Cite

Interferon-alpha (IFN-alpha) has been used to treat hepatitis C Virus (HCV)-induced infection but has been effective in only about half of all patients. It is suggested that the different responses to IFN-alpha treatment in HCV infection may be influenced by HCV genotypes, HCV RNA titer at the beginning of IFN-alpha therapy, and the sequences of the interferon sensitivity determining region (ISDR). However, there have also been reports showing that these have no relation to an IFN-alpha effect. In a previous study, it was found that the nucleotide sequence variation in the hypervariable region (HVR) 1 of the HCV could predict the effect of IFN-alpha. In the present investigation, an attempt was made to determine the predictive factors of IFN-alpha therapy. Twenty-six patients with HCV infection were treated with IFN-alpha. Among these, 13 patients recovered after 3 to 6 months of IFN-alpha treatment, although the other 13 patients showed no response after 6 months of treatment with IFN-alpha. In order to determine the predictive factors of IFN-alpha therapy, the ALT levels, HCV genotypes, HCV serum titer, and the quasispecies of HVR 1 were compared between responders and non-responders. It is suggested that the variation in the HVR 1 and HCV serum titer can be used to predict the effect of IFN-alpha.

show abstract

“…(Evidence level C.) Comment: Ursodeoxycholic acid (UDCA) stabilizes serum ALT levels in HCV-related liver cirrhosis [65], and glycyrrhizin injection is useful for the prevention of disease progression [66]. However, their effects on liver fibrosis have not been confirmed.…”

Section: Antifibrotic Therapymentioning

confidence: 99%

Evidence-based clinical practice guidelines for liver cirrhosis 2015

et al. 2016

View full text Add to dashboard Cite

The Japanese Society of Gastroenterology revised the evidence-based clinical practice guidelines for liver cirrhosis in 2015. Eighty-three clinical questions were selected, and a literature search was performed for the clinical questions with use of the MEDLINE, Cochrane, and Igaku Chuo Zasshi databases for the period between 1983 and June 2012. Manual searching of the latest important literature was added until August 2015. The guidelines were developed with use of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. This digest version in English introduces selected clinical questions and statements related to the management of liver cirrhosis and its complications. Branched-chain amino acids relieve hypoalbuminemia and hepatic encephalopathy and improve quality of life. Nucleoside analogues and peginterferon plus ribavirin combination therapy improve the prognosis of patients with hepatitis B virus related liver cirrhosis and hepatitis C related compensated liver cirrhosis, respectively, although the latter therapy may be replaced by direct-acting antivirals. For liver cirrhosis caused by primary biliary cirrhosis and active autoimmune hepatitis, urosodeoxycholic acid and steroid are recommended, respectively. The most adequate modalities for the management of variceal bleeding are the endoscopic injection sclerotherapy for esophageal varices and the balloon-occluded retrograde transvenous obliteration following endoscopic obturation with cyanoacrylate for gastric varices. Beta-blockers are useful for primary prophylaxis of esophageal variceal bleeding. The V 2 receptor antagonist tolvaptan is a useful add-on therapy in careful diuretic therapy for ascites. Albumin infusion is useful for the prevention of paracentesis-induced circulatory disturbance and renal failure. In addition to disaccharides, the nonabsorbable antibiotic rifaximin is useful for the management of encephalopathy. Anticoagulation therapy is proposed for patients with acute-onset or progressive portal vein thrombosis.

show abstract

Long‐term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease

Cited by 27 publications

References 59 publications

A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients

A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients

Factors predictive of response to interferon‐α therapy in hepatitis C virus type 1b infection

Evidence-based clinical practice guidelines for liver cirrhosis 2015

Contact Info

Product

Resources

About